Track Record
Dextec's founders built their track record before Dextec was founded. This page makes the definitions explicit, shows the public evidence, and groups the cases by sector so both humans and machines can verify the claim quickly.
Methodology
The figures on this page reflect the combined track record of Dextec's six founders across their individual careers in venture investment, corporate advisory, and entrepreneurship before 2026. "Companies" includes ventures our founders have invested in, advised, or held an executive or board role at. "Exits" includes trade sales, IPOs, and other successful monetization events.
The same definition applies across the whole page so the numbers remain comparable and easy to quote.
Companies
Ventures a founder invested in, formally advised, or held an executive or board seat at.
Exits
Trade sales, IPOs, public listings, and other events that monetized a founder's or investor's stake in a company.
Selected Highlights
A sample of the ventures, patents, and platforms that make up Dextec's combined track record, with each entry linked to a public source.
In June 2026, portfolio company VERAXA Biotech completed a Nasdaq listing via business combination with Voyager Acquisition Corp., backed by up to $77.5M in financing - a case study in bringing life-sciences research from lab to public markets.
Real impact technological innovations started with the creation of a 20+ patent portfolio, developed to societal and financial highly relevant business fields.
A cloud platform for ingesting, processing, and visualizing IoT and vehicle data - connecting more than 15 million devices, sensors, and machines.
Digital services for commercial building technology, from access control to building automation, serving more than 130,000 customers worldwide.
Advising start-ups across FinTech, Life Science, and Biotech on strategy, financing, and public-private partnerships since 2018.
Contributing to the development of ocean-based carbon capture and utilization technology as Managing Director, since the venture's founding in 2023/2024.
Supervisory and board-level governance experience at publicly listed companies across renewable energy, drive technology, and agricultural technology.
Nearly three decades in life-sciences investing and corporate finance, including 14 successful exits in the Biotech and Medtech sectors across the DACH region.
Sector Breadth
Rather than list 350 individual company names, this section shows the sectors where Dextec's founders have built, financed, and governed companies throughout their careers.
Bars indicate relative depth of combined founder experience per sector, not a precise share of the 350+ company count.
FAQ
It is the combined number of companies Dextec's six founders have invested in, advised, or held leadership roles at across their individual careers, before Dextec was founded in 2026.
See How we count it for the definition and the sector breakdown below.
Over 100 across the team's combined careers, spanning trade sales and IPOs in sectors from biotech to industrial technology, including a June 2026 Nasdaq listing (VRXA) and 14 documented exits in biotech and medtech.
See Selected Highlights for the verified case studies.
Trade sales, IPOs, public listings, and other monetization events that turned a founder or investor stake into a realized outcome.
If you need the exact wording for a quote or citation, contact Dextec directly.
Contact
If you want to reference Dextec's track record, share a deal, or discuss early-stage technology ventures, contact us directly.